Nifty
Sensex
:
:
13055.15
44523.02
128.70 (1.00%)
445.87 (1.01%)

Pharmaceuticals & Drugs - Veterinary

Rating :
71/99  (View)

BSE: 512529 | NSE: SEQUENT

155.65
-2.50 (-1.58%)
24-Nov-2020 | 3:58PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  158.90
  •  159.65
  •  154.65
  •  158.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  926889
  •  1442.70
  •  168.75
  •  51.70

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,927.99
  • 49.51
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 4,182.81
  • N/A
  • 5.25

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.51%
  • 10.31%
  • 17.57%
  • FII
  • DII
  • Others
  • 8.37%
  • 4.64%
  • 4.60%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.22
  • 13.54
  • 4.59

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.11
  • 24.60
  • 8.84

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 2.97
  • 15.48
  • -45.06

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 4.04
  • 30.59

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.34
  • 3.12
  • 2.75

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 57.29
  • 28.83
  • 15.71

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
346
284
22%
310
278
12%
301
282
7%
316
271
17%
Expenses
290
247
17%
259
240
8%
256
243
5%
266
235
13%
EBITDA
56
37
52%
51
38
33%
45
39
15%
50
36
40%
EBIDTM
16%
13%
16%
14%
14%
14%
16%
13%
Other Income
3
6
-56%
2
1
18%
2
2
-25%
1
2
-51%
Interest
7
8
-6%
8
9
-15%
9
9
5%
10
8
15%
Depreciation
13
12
7%
13
12
8%
13
11
20%
13
11
17%
PBT
29
23
28%
32
19
70%
24
22
12%
28
18
56%
Tax
8
-2
-
7
4
112%
6
0
2011%
4
3
63%
PAT
21
24
-13%
24
15
60%
18
21
-14%
24
16
55%
PATM
6%
9%
8%
6%
7%
8%
8%
6%
EPS
0.86
0.98
-12%
0.99
0.62
60%
0.73
0.86
-15%
0.97
0.63
54%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
1,274
1,179
1,039
1,031
684
625
465
455
327
346
312
Net Sales Growth
14%
13%
1%
51%
9%
34%
2%
39%
-5%
11%
 
Cost Of Goods Sold
5,146
605
543
554
357
312
241
244
182
192
162
Gross Profit
-3,872
574
496
476
327
313
225
212
145
154
150
GP Margin
-304%
49%
48%
46%
48%
50%
48%
46%
44%
44%
48%
Total Expenditure
1,071
1,009
914
919
643
568
445
439
343
309
266
Power & Fuel Cost
-
25
23
15
13
27
23
22
24
20
17
% Of Sales
-
2%
2%
1%
2%
4%
5%
5%
7%
6%
5%
Employee Cost
-
165
146
132
106
89
62
48
41
29
30
% Of Sales
-
14%
14%
13%
16%
14%
13%
11%
13%
8%
10%
Manufacturing Exp.
-
83
78
59
58
72
54
52
41
28
34
% Of Sales
-
7%
7%
6%
8%
12%
12%
11%
13%
8%
11%
General & Admin Exp.
-
56
58
71
49
36
34
44
24
14
16
% Of Sales
-
5%
6%
7%
7%
6%
7%
10%
7%
4%
5%
Selling & Distn. Exp.
-
45
36
37
29
17
20
12
11
9
8
% Of Sales
-
4%
3%
4%
4%
3%
4%
3%
3%
3%
2%
Miscellaneous Exp.
-
29
30
51
32
15
10
17
20
16
8
% Of Sales
-
2%
3%
5%
5%
2%
2%
4%
6%
5%
0%
EBITDA
202
170
125
111
41
57
20
17
-16
37
46
EBITDA Margin
16%
14%
12%
11%
6%
9%
4%
4%
-5%
11%
15%
Other Income
7
10
9
17
11
14
10
4
5
10
7
Interest
34
36
33
40
28
39
44
39
33
30
24
Depreciation
52
51
42
53
40
46
33
33
29
23
21
PBT
114
94
59
36
-17
-14
-47
-51
-73
-5
8
Tax
26
12
2
13
0
3
3
1
-8
-4
8
Tax Rate
22%
13%
3%
3%
2%
-19%
-40%
-1%
11%
73%
216%
PAT
88
70
49
422
-14
-18
-11
-110
-65
-1
0
PAT before Minority Interest
81
82
57
431
-16
-16
-12
-110
-65
-1
-4
Minority Interest
-7
-12
-8
-9
3
-2
1
0
0
0
4
PAT Margin
7%
6%
5%
41%
-2%
-3%
-2%
-24%
-20%
0%
0%
PAT Growth
15%
44%
-88%
3,148%
25%
-72%
90%
-71%
-4,521%
-724%
 
EPS
3.55
2.81
1.96
16.97
-0.56
-0.74
-0.43
-4.45
-2.60
-0.06
-0.01

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
743
707
648
977
946
91
57
95
123
123
Share Capital
50
49
49
49
48
30
27
23
21
21
Total Reserves
679
638
581
912
874
27
0
60
101
102
Non-Current Liabilities
242
215
227
246
300
278
159
144
105
123
Secured Loans
108
127
85
142
198
250
151
137
80
91
Unsecured Loans
42
21
18
23
14
0
1
1
1
8
Long Term Provisions
13
30
29
35
29
26
8
6
15
12
Current Liabilities
480
440
431
664
290
406
405
345
330
199
Trade Payables
220
209
160
203
144
91
115
151
124
83
Other Current Liabilities
93
88
107
259
83
107
57
36
75
38
Short Term Borrowings
134
127
152
195
56
204
227
152
123
69
Short Term Provisions
32
16
12
7
7
3
7
7
7
10
Total Liabilities
1,509
1,402
1,343
1,904
1,538
922
626
589
562
446
Net Block
632
498
476
684
586
474
238
227
230
211
Gross Block
818
638
582
790
644
596
369
331
305
264
Accumulated Depreciation
186
140
106
105
57
122
131
103
75
54
Non Current Assets
795
796
805
1,176
1,047
612
360
358
352
282
Capital Work in Progress
13
23
18
33
24
39
43
89
64
20
Non Current Investment
131
180
222
364
361
58
0
2
0
0
Long Term Loans & Adv.
14
32
31
38
30
36
76
39
56
51
Other Non Current Assets
3
63
58
58
47
4
3
1
2
1
Current Assets
714
606
538
728
491
310
266
231
210
164
Current Investments
40
0
17
64
67
1
0
0
0
0
Inventories
219
200
159
161
135
94
101
86
68
66
Sundry Debtors
319
278
258
255
192
115
84
66
70
55
Cash & Bank
76
72
42
47
25
38
36
33
36
9
Other Current Assets
60
9
5
146
71
61
45
46
36
34
Short Term Loans & Adv.
44
47
56
54
47
42
37
36
29
31
Net Current Assets
235
166
107
64
200
-96
-139
-114
-119
-35
Total Assets
1,509
1,402
1,343
1,904
1,538
922
626
589
562
446

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
115
116
45
-7
0
-24
-45
-4
21
50
PBT
94
59
446
-17
-14
-8
-110
-73
-5
3
Adjustment
91
84
-314
123
84
36
134
66
47
37
Changes in Working Capital
-58
-28
-78
-104
-71
-54
-67
2
-17
16
Cash after chg. in Working capital
127
115
54
2
-1
-26
-44
-4
24
56
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-12
1
-9
-9
1
3
-1
0
-3
-7
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-72
-68
7
-116
-316
-155
-80
-55
-67
-72
Net Fixed Assets
-30
-33
222
-50
98
39
-27
-29
-42
-81
Net Investments
31
-102
210
0
-714
-118
-10
-16
-25
32
Others
-73
67
-425
-67
300
-75
-43
-10
0
-22
Cash from Financing Activity
-43
-20
-57
147
309
179
146
35
62
17
Net Cash Inflow / Outflow
0
28
-5
24
-7
1
21
-24
17
-6
Opening Cash & Equivalents
68
40
44
20
22
23
3
27
9
14
Closing Cash & Equivalent
68
68
40
44
20
22
23
3
27
9

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
29
28
26
39
39
4
2
7
11
12
ROA
6%
4%
27%
-1%
-1%
-2%
-18%
-11%
0%
-1%
ROE
12%
9%
54%
-2%
-3%
-28%
-202%
-63%
-1%
-3%
ROCE
12%
9%
41%
1%
3%
7%
-16%
-10%
7%
9%
Fixed Asset Turnover
1.65
1.74
1.51
0.96
1.03
1.01
1.36
1.08
1.26
1.31
Receivable days
90
93
90
118
88
75
57
73
64
63
Inventory Days
64
62
56
78
65
74
72
82
68
69
Payable days
81
75
77
104
77
87
116
149
123
94
Cash Conversion Cycle
73
79
70
93
76
61
13
6
9
38
Total Debt/Equity
0.45
0.47
0.48
0.43
0.34
8.26
15.86
3.74
2.19
1.54
Interest Cover
4
3
12
0
1
1
-2
-1
1
1

News Update


  • Sequent Scientific completes acquisition of 40% stake in Provet
    3rd Nov 2020, 10:45 AM

    On completion of the said transaction, Provet has become a Wholly Owned Subsidiary of the Company

    Read More
  • India Ratings and Research upgrades Sequent Scientific's credit ratings with positive outlook
    12th Oct 2020, 12:51 PM

    The Credit rating agency has upgraded the Sequent Scientific's Long-Term Issuer Rating to 'A' from 'A-'

    Read More
  • Sequent Scientific completes acquisition of 15% stake in Fendigo BV
    9th Oct 2020, 16:51 PM

    On completion of the said transaction, Fendigo BV has become a Wholly Owned Subsidiary of the Company

    Read More
  • Sequent Scientific completes sale of investments held in Strides Pharma
    26th Sep 2020, 09:55 AM

    The proceeds of the sale will be predominantly utilised to consolidate the company’s shareholding in Provet

    Read More
  • Sequent Scientific gets shareholders’ nod to acquire 40% stake in Provet
    23rd Sep 2020, 09:43 AM

    The said transaction is expected to be completed on or before October 31, 2020

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.